Screener
Neurocrine Biosciences NBIX Asset turnover
Asset turnover at other companies
Other financials
Where this comes from
Calculated from Neurocrine Biosciences’s reported figures.
Based on trailing twelve months.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
FAQ
- What is Neurocrine Biosciences's asset turnover?
- Neurocrine Biosciences (NBIX) reported asset turnover of 0.7× in Q1 2026.
- How has Neurocrine Biosciences's asset turnover changed year-over-year?
- Neurocrine Biosciences's asset turnover increased by 7.1% year-over-year, from 0.7× to 0.7×.
- What is the long-term trend for Neurocrine Biosciences's asset turnover?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's asset turnover has grown at a -0.1% compound annual growth rate (CAGR), from 0.7× to 0.7×.
- What does asset turnover mean?
- Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.
Ask your AI about Neurocrine Biosciences's asset turnover.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude